Pernix Therapeutics (PTX) Target Price Bumped Higher at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Pernix Therapeutics Holdings (PTX) Posts Q4 Loss of 15c/Share
March 17, 2014 8:05 AM EDTPernix Therapeutics Holdings (Nasdaq: PTX) reported Q4 EPS of ($0.15), $0.05 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $23.9 million versus the consensus estimate of $23.82 million.
For earnings history and earnings-related data on Pernix Therapeutics Holdings (PTX) click here.... More
